In neurosurgery, anticoagulating agents have not gained wide acceptance because of fear that they will cause intracranial bleeding. Nevertheless, recent studies indicate that 40 mg enoxaparin administered subcutaneously, as well as other low-molecular-weight heparins, can be used safely and efficiently for the prevention of venous thromboembolism after neurosurgical procedures, 1, 24 the majority of which in these previous studies, however, have been for brain tumor or spinal disorders.
On the basis of its well-established effects as a preventive agent for blood coagulation, enoxaparin may have a beneficial effect on brain circulation, on acute and delayed ischemia, and thus also on final outcome after SAH. The aim of this study, therefore, was to investigate enoxaparin's effect on outcome after aneurysmal SAH.
Clinical Material and Methods

Patient Population
This study was approved by the research ethics committee of the local institutional review board. All patients, or, in cases of inspired consciousness, their closest relatives, gave prior written informed consent before entry into the study. Between February 1998 and March 2001, 546 patients with aneurysmal SAH were surgically treated at our institution, which is the only neurosurgical unit serving a population of almost 2 million. Of these 546 cases, 170 patients (31%) fulfilled our criteria and were enrolled in the study.
The entry criteria were as follows: 1) that aneurysmal SAH was verified on CT scans, and the location of the aneurysm was verified either with digital subtraction or CT angiography; 2) that the study drug was started within 72 hours post-SAH; and 3) 12 to 24 hours before the start of injections the ruptured aneurysm was secured with open surgery (clip occlusion, 163 patients), endovascular coil placement (four patients), or proximal clip occlusion or trapping of the parent artery (three patients).
The exclusion criteria were as follows: 1) hospital admission occurred too late (the proportion of patients excluded for this reason was 33% of 546); 2) the patient was older than 75 years of age (5%); 3) ICH greater than 20 mm in diameter on postoperative CT scans: patient was excluded because of a possibility of increase in ICH size (26%); 4) recent gastrointestinal bleeding, other bleeding disorder, or ongoing anticoagulation treatment; 5) blood pressure higher than 200/110 mm Hg after admission; 6) severe renal or liver disorder, or severe preexisting neurological disease; 7) pregnancy; 8) allergy to heparin; and 9) postoperative hemoglobin level less than 100 g/L, thromboplastin time less than 50%, platelet count less than 100 ϫ 10 9 /L, or activated partial thromboplastin time longer than 100 seconds (total for points 4-9: 5%).
Study Design
This prospective, randomized, placebo-controlled, double-blind study was conducted at a single center. The primary end point was ability of enoxaparin to improve overall clinical outcome in patients with aneurysmal SAH, as estimated with the GOS 16 and mRS 2 at 3 months post-SAH. Secondary end points included effects of enoxaparin on the following: 1) incidence of DIND; 2) surgical complications; 3) thromboembolic complications; 4) increase in ICH volume; and 5) shunt-dependent hydrocephalus.
After the ruptured aneurysm had been secured and postoperative CT scans confirmed the absence of major ICH (Ͼ 20 mm in diameter), eligible patients were randomly assigned to receive either enoxaparin (Klexane, 100 anti-factor Xa U/mg; Rhône-Poulenc Rorer, Antony, France. Factory at which the drug was manufactured: Laboratories Fisons, Le-Trait, France) at a dose of 40 mg per day or placebo (saline), both administered subcutaneously, with 85 patients in each group. Enoxaparin and placebo preparations were made up at the hospital pharmacy from commercially available medicine, with blocked randomization (block size four). This method of preparing the study medicine ensured that there would be no financial conflict of interest.
The postoperative CT scan and angiogram were checked before the start of study drug administration. The first dose had to be given within 72 hours after the most recent hemorrhage and continued for 10 days. The safety and effectiveness of the treatment was verified by the presence of anti-factor Xa activity assessed by a laboratory technician blinded to patient identity and case history. In no case was treatment discontinued because of an overeffect of a study medicine (activity Ͼ 0.7 U/ml). In case of reoperation (including ventriculostomy), the study drug was halted and then continued on the following day. Patients with bleeding complications were described in detail to members of the safety committee of the study.
Treatment Options
The mean time to occlusion of the ruptured aneurysm was 25 hours (range 5-60 hours).
Nimodipine was routinely administered intravenously for 10 to 12 days after SAH and perorally thereafter, up to Day 21. 25 Causes of neurological deterioration were recognized and treated according to standard medical, pharmacological, and surgical management. Induced hypertension, hypervolemia, or endovascular treatment of delayed ischemia, or both, were used when necessary. No treatment with aspirin, other antiplatelet agents, or nonsteroidal antiinflammatory drugs was permitted.
Clinical Monitoring and Outcome
The clinical condition of the patients on admission and before surgery was graded according to the World Federation of Neurosurgical Societies scale. 32 Neurological examinations were performed daily after admission, and compliance with the study medication was checked. Gradual deterioration in the level of consciousness or the onset of classic symptoms of DIND (worsening of headache, stiff neck, confusion, disorientation, drowsiness, or focal neurological deficit) were considered indicative of the presence of DIND after other causes of the symptoms had been ruled out.
Patients were discharged no earlier than 10 days after the start of medication, because both the study drug and routinely administered intravenous nimodipine continued for that length of time. All patients were examined 3 months post-SAH in the outpatient department to assess outcome according to the GOS and mRS.
Computerized tomography studies were obtained at the following times: on admission, on the 1st postoperative day, in cases of neurological deterioration, and at discharge (at cessation of the study medication). The amount of subarachnoid blood observed on CT scans was graded according to Fisher, et al. 8 Angiograms were obtained in all patients pre-and postoperatively. All neuroimaging studies were examined by two experienced neuroradiologists (M.P. and K.P.).
Statistical Analysis
Calculation of sample size was based on an expected incidence of good recovery of 65% of patients in the control group, based on previous studies in our clinic, 17, 25 and of 85% for the enoxaparin group. Approximately 164 patients (82 in each study arm) would be needed to detect this 20% improvement in good recovery rate at an alpha level of 0.05 (two-tailed) and a beta level of 0.2.
Data were analyzed using a commercially available statistical package (SPSS for Windows, version 9.0.1.; SPSS, Inc., Chicago, IL). Categorical variables were compared using the Fisher exact two-tailed test, the Pearson chi-square test, or the test for linear trend. Continuous variables were compared between groups by using the Mann-Whitney U-test or Student t-tests. A probability value less than 0.05 was considered significant.
Results
For baseline characteristics of the patients, see Table 1 . The groups were well balanced with respect to characteristics, with the only significant difference being the occurrence of small ICHs. Antifactor-Xa activity was similar in both treatment groups before the start of the injections (enoxaparin compared with placebo groups: 0.07 Ϯ 0.02 and 0.07 Ϯ 0.01 U/ml). At 3 hours after the start of the injections, anti-factor Xa activity was significantly higher in the enoxaparin group (0.35 Ϯ 0.12 compared with 0.06 Ϯ 0.004 U/ml, p Ͻ 0.001).
Outcome at 3 Months
Outcome by treatment group is presented in Table 2 . No statistically significant differences appeared in GOS and mRS scores by treatment groups. Nevertheless, patients who received placebo treatment tended to have better mRS scores, despite their being in somewhat worse condition on admission than were those who received enoxaparin. In detailed analysis, the reasons for a little less favorable outcome in the enoxaparin group were several and could not be linked to enoxaparin's antithrombotic effect.
During the follow-up period, seven deaths occurred in the enoxaparin and four in the placebo group. Causes of death in the enoxaparin group were as follows: primary bleeding, rebleeding occurring before start of enoxaparin treatment, DIND with severe angiographically confirmed vasospasm, surgical technical complications (one patient each), and pneumonia (three patients). In the placebo group, causes of death were pulmonary embolism (one patient) and pneumonia (three patients). Similarly, there were a few more main causes of deterioration in the enoxaparin than in * ACA = anterior cerebral artery; ACoA = anterior communicating artery; ICA = internal carotid artery; MCA = middle cerebral artery; SD = standard deviation; WFNS = World Federation of Neurosurgical Societies.
† Study groups were well matched as to baseline characteristics, but with more small ICHs in the placebo group.
‡ Borderline hypertension was defined as pre-SAH blood pressure between 140/90 and 160/95 mm Hg, with or without antihypertension medication. Definite hypertension was defined as blood pressure higher than 160/95 mm Hg with or without antihypertension medication.
§ Heavy alcohol use was defined as approximately 300 g of absolute ethanol or more per week.
|| Defined as more than 1 mm of blood in vertical layers on CT scans. ** p Ͻ 0.05.
the placebo group: prolonged poor initial condition (22 compared with 19 patients), premedication rebleeding (four compared with two), DIND (16 compared with 12), surgical complications (15 compared with 13), and other (four compared with five).
Delayed Cerebral Ischemia
The incidence of DIND was 26.5% of all patients, with no difference between study groups (Table 3) ; 10% had reversible ischemia, and 16.5% had ischemia causing fixed neurological deficit. Endovascular treatment for vasospasm was used in two patients in the enoxaparin and in one patient in the placebo group.
Other Clinical Events
Surgical complications occurred in 24 patients (28%) in the enoxaparin group and 19 (22%) in the placebo group (Table 3) . Of these complications, 13 in the enoxaparin and eight in the placebo group were caused by occlusion, either of the parent or perforating artery.
Although shunt-dependent hydrocephalus was present in 32 (19%) of these 170 patients, hydrocephalus was the main reason for deterioration in only one patient in the placebo and two in the enoxaparin group. The placebo group had three patients with DVT (occurring in one case after cessation of treatment) and one fatal pulmonary embolism as well, although it occurred at 5 weeks after SAH. The enoxaparin group had one patient with DVT that was diagnosed 1 month after SAH.
Drug Safety and Study Compliance
Violation of the study protocol occurred in 12 patients (14.1%) in each group. In 10 cases per group, the study drug was halted for 1 day due to surgery (repeated operation, ventriculostomy, shunt placement) but was continued for a total of 10 days thereafter, except for 11 cases, in which the total period of treatment was from 7 to 9 days. Some of the latter violations included lack of administration of the study medicine.
In the placebo group, two patients with DVT demanded verified effective low-molecular-weight heparin treatment instead of the study medicine. In the enoxaparin group, one patient suffered intraoperative, premature rupture of the aneurysm treated with surgical closure of the anterior communicating artery. This patient received only one dose of enoxaparin after surgery, and her intraventricular hemorrhage increased in size. This increase was likely due to ventriculostomy, but the study medicine nevertheless had to be halted. In another patient, the size of a small ICH increased slightly after 5 days of treatment, and the medication was stopped. A CT scan obtained in this patient 10 days post-SAH revealed no additional ICH.
Comparison of admission CT scans and those obtained postsurgery, before randomization, with those obtained at the end of the course of medication showed that two patients had new, asymptomatic, small hemorrhages, both of them in the enoxaparin group. One patient had an ICH less than 10 mm in diameter and another had a subdural hematoma that was later evacuated. The latter case was reviewed by the safety committee, and the study was not halted. Overall, enoxaparin did not significantly increase bleeding complications.
Discussion
We report that prophylactic use of enoxaparin (40 mg administered subcutaneously once a day) had no beneficial effect on the outcome of patients with SAH who had already received nimodipine and triple-H therapy when needed.
Cerebral Ischemia After SAH
Cerebral blood flow is known to be impaired from the time of aneurysm rupture onward and is the main determinant of outcome after SAH. Approximately 25 to 40% of patients with SAH suffer from DIND, causing neurological worsening and permanent deficits. 20, 29, 30 This condition has been treated by pharmacological (endothelin receptor antagonists, nimodipine) or mechanical (endovascular treatment of vasospasm or hypervolemic therapy) arterial dilation. Alternatively, the key idea has been protection of the brain from ischemic injury (Ca ϩϩ channel-blocking agents or tirilazad mesylate) or improvement of blood rheological properties (triple-H therapy and nimodipine). Of these treatments, the ones in widest clinical use are Ca ϩϩ channelblocking agents (nicardipine and nimodipine) and triple-H therapy.
One thing these two DIND treatments have in common is the attempt through better blood rheology to improve circulation in the brain. In fact, the main cause of nimodipine's favorable effect on DIND may be its antiplatelet aggregating effect and improvement of blood rheology. 6, 18 In accordance with this, activation of the coagulation-fibrinolysis system shows a clear correlation with clinical condition, outcome, and mortality rate in patients with SAH as well as with development of brain infarcts. 26 Furthermore, in patients with SAH, increased platelet aggregation as well as production of thromboxane A 2 correlates with brain isch- emia. 18 In short, because the blood of patients prone to poor outcome after aneurysmal SAH seems to be in a hypercoagulative state, anticoagulation may help improve their outcome.
Low-Molecular-Weight Heparins
Low-molecular-weight heparins such as enoxaparin are a fractionated component of heparin. 3, 28, 34 Low-molecularweight heparins are longer acting, and due to their smaller size have greater anti-factor Xa/anti-factor IIa activity than does standard heparin, thus exerting their effect mainly through factor Xa inactivation. Furthermore, low-molecular-weight heparins support the release of the natural anticoagulant tissue factor pathway inhibitor. 15 Low-molecularweight heparins inhibit thrombin generation and may limit fibrin formation, thus acting also in microvessels that may play a central role in the pathogenesis of DIND. 15, 21, 33 Furthermore, these agents have been suggested to have additional neuroprotective effects, possibly explained by their antiinflammatory properties, 22 which also may be part of the mechanism of pathogenesis of DIND. 21, 33 Several studies and metaanalyses have shown that low-molecular-weight heparins are at least as efficient as well as safer than standard heparin in preventing and treating DVT, pulmonary embolism, and unstable coronary disease. 3, 4, 34 In experimental mouse ischemic stroke models, enoxaparin seems to offer good neuroprotection and reduce ischemic lesion size by 49%. 22 Similarly, Kay, et al., 19 showed in 1995 that the low-molecular-weight heparin nadroparin improves outcome after clinically confirmed stroke at 6 months (but not at 10 days or 3 months) in a dose-dependent manner.
In short, enoxaparin is a widely used, effective anticoagulant known to have beneficial effects on factors associated with poor outcome after SAH. Nevertheless, 40 mg enoxaparin delivered subcutaneously once a day had no effect on SAH outcome according to our study, as judged by the GOS and mRS 3 months after the initial hemorrhage.
Possible Explanations of Negative Results
Dose. Enoxaparin has a half-life of action of 4 hours. It therefore remains possible that a better effect on brain circulation would have been achieved by dividing this 40-mg dose into two equal doses per day. For DVT prophylaxis, however, 40 mg once a day is standard and is known to be effective. For treatment of DVT or pulmonary embolism, conversely, the treatment dose would be 1 mg/kg twice daily, that is, almost four times the present prophylactic dose. This type of full heparinization dose may prevent stroke recurrence but seems to increase the risk for hemorrhagic complications even further. 5 It would therefore have been difficult to justify a higher dose in our study, to be delivered 12 to 24 hours after craniotomy for ruptured aneurysm.
Prophylactic doses were also used in previous safety studies, but these investigations were conducted for indications other than SAH (mainly spinal and brain tumor surgery). 1, 7, 24 Furthermore, a higher dose (30 mg twice daily) of enoxaparin for neurosurgical patients, started at the time of anesthesia induction, has led to an increased rate of postoperative hematomas and the cessation of one study. 7 Thus, use of the lower, prophylactic dose was considered justified in an attempt to improve outcome after aneurysmal SAH. Heparins, Heparinoids, and Stroke. Despite the widespread use of heparins after stroke, the effect of heparinization on basilar artery thrombosis, cardiogenic emboli, and "stroke in progress" has recently been questioned. 5 Furthermore, a recent study of full, intravenously delivered anticoagulation therapy in which a heparinoid (danaparoid) was used in 1281 patients within 24 hours of onset of acute ischemic stroke (the TOAST study) 27 showed no net benefit overall or even for cardioembolic stroke, thus challenging results by Kay, et al. 19 The rationale for low-molecularweight heparin in ischemic stroke and after SAH differs somewhat, however. In ischemic stroke, blood is not in contact with extravascular tissues. Moreover, in ischemic stroke, brain ischemia has already taken place, whereas in SAH, DIND occurs a few days after aneurysm rupture.
Irreversibility of Vascular Damage. The present active treatments affecting the potentially reversible portion of DIND may already be maximized; this is supported by a decrease in incidence of DIND during recent decades. For instance, patients receiving tirilazad mesylate do not seem to need as much triple-H therapy, but in the end the outcome is the same. 20 Delayed ischemia leading to irreversible damage (fixed neurological deficit) despite maximal care may result from irreversible endothelial damage taking place during the initial hemorrhage. From this point of view, the coagulation disorder could be the result of, not the reason for, the primary damage that later leads to partially irreversible DIND.
Other Clinical Factors Affecting Outcome. Many clinical factors that are beyond the effects of enoxaparin have an effect on final outcome after SAH. Recent Swedish population-based data indicate that a more important reason than DIND for poor outcome after SAH is early rebleeding. 13 Our patients had no rebleeding from secured aneurysms. Surgery on the ruptured aneurysm itself causes considerable morbidity and even death. Our total surgical complication rate was 25.3% (it was the main cause of patient deterioration in 16.5%), a rate similar to that of DIND. Recent data from Sweden show a surgical complication rate of up to 30%, resulting in poor outcome in 7.9% of the surgically treated patients. 9 Our surgical complication rate was not affected by enoxaparin treatment.
Thromboembolic Complications and Safety
The effect of enoxaparin in preventing DVT has been verified in numerous large clinical studies and metaanalyses. [3] [4] [5] Our series showed a low rate of clinical thromboembolic complications in both study groups, because venography was not routinely used to detect asymptomatic DVTs. Agnelli, et al., 1 found the incidence of DVT determined using routine venography in neurosurgical patients to be 32% without and 17% with enoxaparin prophylaxis. The incidence of symptomatic DVT, however, was 6% without and 1% with prophylaxis, similar to the findings in our study. Agnelli, et al., thus considered a prophylactic dose of enoxaparin safe for neurosurgical patients.
Low-molecular-weight heparins administered after SAH have still been considered potentially harmful because of the possibility of intracranial bleeding. 12 Based on our find-ings, the enoxaparin group seemed to have a slight but statistically nonsignificant increase in the number of bleeding complications compared with the placebo group. Four separate bleeding complications occurred in our enoxaparin group, compared with none in our placebo group. These complications were not related to the outcome at 3 months. Two of the bleeding complications led to withdrawal of the study drug, and another two were found on routine CT scans. This trend toward increased risk for bleeding complications is, however, offset by the verified decreased risk of thromboembolic complications. Finally, the incidence of DVT after SAH has been high (14-18%). 11, 31 Patients in poor clinical condition and on prolonged bedrest may need treatment with anticoagulation agents. Prophylactic use of enoxaparin may thus be helpful after surgery for a ruptured aneurysm, but only for prevention of venous thromboembolic complications in poor-grade patients in whom prolonged bedrest is prescribed.
Conclusions
Despite the theoretical appeal of enoxaparin for patients with SAH, our results do not encourage its use to improve outcome after SAH. Routine use of low-molecular-weight heparin should be avoided during the early postoperative period after surgery for a ruptured aneurysm because its use seems to increase intracranial bleeding complications slightly, with no beneficial effect on neurological outcome.
